Key Highlights

  • Loss per share was USD 0.47 against an estimate of a USD 0.74 loss.
  • Net loss was USD 97.2 million, compared with USD 126.5 million a year earlier.
  • Total operating expenses were USD 104.2 million, compared with USD 131.8 million.
  • Cash and cash equivalents were USD 722.3 million as of September 30, 2026.

Immunovant (NASDAQ:IMVT) reported a loss per share of USD 0.47 for the fiscal quarter ended September 30, 2026, compared with an estimate of a USD 0.74 loss. Net loss was USD 97.2 million, compared with USD 126.5 million in the same quarter a year earlier.

Total operating expenses were USD 104.2 million, against USD 131.8 million. The company's fiscal year ends March 31, so the quarter ended September 30, 2026 is its second fiscal quarter. The filing notes that accrued clinical trial costs are estimated from services received, patient enrollment and the rate of enrollment. For the six months, net loss was USD 250.5 million, compared with USD 247.1 million, and total operating expenses were USD 264.5 million, compared with USD 259.0 million.

Research and Development Costs

The filing states that therapeutic area-specific Research and Development costs, including contract Manufacturing costs, decreased USD 18.3 million from the prior-year quarter. Unallocated research and development costs decreased USD 10.9 million. General and administrative expenses were USD 6.4 million, compared with USD 5.5 million, an increase of USD 1.6 million that the filing attributes primarily to higher Investment in pre-commercial activities.

General and administrative expenses for the six months were USD 12.7 million, compared with USD 16.0 million in the prior-year period. Interest income increased USD 1.3 million, which the filing links to higher average Money Market fund balances, partly offset by lower average interest rates.

Liquidity and Funding Outlook

The company had cash and cash equivalents of USD 722.3 million as of September 30, 2026, compared with USD 902.1 million as of March 31, 2026. The filing states that, based on its current operating plan, the company's existing cash is sufficient to fund operating expenses and Capital Expenditure requirements through the potential commercial launch of IMVT-1402 in Graves' disease.

Pipeline Focus

The company describes a broad anti-FcRn strategy built on IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor. The filing says IMVT-1402 is delivered as a subcutaneous injection and has been observed to reduce immunoglobulin G antibody levels. The filing states that the company's primary focus is to execute on its lead indications first, with plans to assess new indications for the antibody in the future. It references Phase 2 and 3 studies of batoclimab in Graves' disease and myasthenia gravis, and an analysis in chronic inflammatory demyelinating polyneuropathy showing that IgG reductions of 70% or greater led to better outcomes. The company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402, and it holds a license agreement with HanAll Biopharma Co., Ltd.

Immunovant Fiscal Q2 2027 Earnings: Key Takeaways

Immunovant reported a fiscal second quarter 2027 loss per share of USD 0.47, a net loss of USD 97.2 million and total operating expenses of USD 104.2 million. Cash and cash equivalents stood at USD 722.3 million, which the company states funds operations through the potential commercial launch of IMVT-1402 in Graves' disease.